0.05
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adherium
Its shares trade on ASX under the ticker ADR.AX. It has been listed since 26 August 2015. In the fiscal year to 30 June 2026, it reported revenue of A$2.1m and a net loss of A$14.2m. At that date it held total assets of A$4.6m and shareholders' equity of −A$1.3m.
Adherium Ltd. engages in the development, manufacture, and supply of connected medical devices and respiratory medications used by patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-26. The firm is focused on patient medication adherence, remote monitoring and data management solutions for patients, payers and providers. The Company’s Hailie sensor technology and cloud-based data platform provides real-time feedback on patients' use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and chronic obstructive pulmonary disease (COPD), and reduces direct and indirect healthcare costs. The Company’s technologies include The Hailie Remote Patient Management (RPM) Solution, The Hailie Sensors and The Hailie Solution. Its Hailie solution is a cloud-based platform, which captures medication use data from Food and Drug Administration (FDA)-cleared Bluetooth enabled sensors, which wrap around patient inhalers and provide real-time feedback to patients via the Hailie application and to their physicians via the Hailie portal.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 26 Aug 2015
- Website
- adherium.com ↗
Leadership
Pay as last reported
- Mr. Louis PanaccioExecutive Chairman of the Board, since 2022
- Ms. Dawn BitzChief Executive Officer
- Mr. Geoff FeakesChief Technology Officer
- Mr. Timothy HouchinVice President - Sales
- Mr. Vik PandaVice President of Marketing
- Mrs. Tara Creaven-capassoVice President - Quality, Regulatory and Clinical Affairs
- Mr. Francis WhiteVice President - Global Business Development
- Ms. Julia ChambersHead of Corporate Development
- Mr. Nigel DevineHead of Manufacturing – Consultant
- Ms. Jane LaponHead of Global Market Access and Reimbursement
- Ms. Bronwyn Le GriceHead of Commercial Development and Corporate Affairs, since 2016
- Mr. Chris ManderHead of Regulatory and Quality Affairs
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adherium Ltd. develops connected medical devices for respiratory medications.
- The company's Hailie sensor technology provides real-time patient medication adherence data.
- Hailie Solution is a cloud-based platform FDA-cleared for inhaler use monitoring.
Weaknesses
- The company's focus on respiratory medications limits its market scope.
- Adherium's technologies are specific to inhaler use, reducing versatility.
- The firm's IPO date is 2015-08-26, indicating a relatively recent market entry.
Opportunities
- Expanding Hailie technology to other medical devices could increase market reach.
- Growing demand for remote patient monitoring solutions presents expansion potential.
- Partnerships with pharmaceutical companies may enhance product adoption.
Threats
- Competition in the connected medical device market could impact market share.
- Regulatory changes affecting FDA-cleared devices might disrupt operations.
- Economic downturns could reduce healthcare spending on new technologies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.